Scarica l'app Stockscreener
65.73
9.31%
5.60
Dopo l'orario di chiusura:
65.73
Precedente Chiudi:
$60.13
Aprire:
$61.11
Volume 24 ore:
61,087
Relative Volume:
0.59
Capitalizzazione di mercato:
$611.21M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
+3.95%
1M Prestazione:
+95.68%
6M Prestazione:
+12.86%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$60.08
$66.01
Intervallo di 1 settimana:
$55.10
$66.01
Portata 52W:
$30.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
ONE KENDALL SQUARE. BUILDING 600-700, CAMBRIDGE
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-10 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Iniziato | Cowen | Outperform |
| 2019-10-28 | Iniziato | Goldman | Buy |
| 2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio (NASDAQ:KRRO) Shares Gap DownShould You Sell? - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN
Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks
RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa
Royal Bank of Canada Boosts Korro Bio (NASDAQ:KRRO) Price Target to $105.00 - MarketBeat
Korro Bio initiated with a Strong Buy at Raymond James - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock - Investing.com India
Insider Selling: Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells 10,216 Shares of Stock - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock By Investing.com - Investing.com Australia
Korro Bio shares target lifted, buy rating on RNA editing potential - Investing.com
Korro Bio (NASDAQ:KRRO) Trading Down 4.1%Should You Sell? - MarketBeat
HC Wainwright Increases Korro Bio (NASDAQ:KRRO) Price Target to $115.00 - MarketBeat
Korro Bio price target raised to $115 from $100 at H.C. Wainwright - TipRanks
BMO maintains steady target on Korro Bio shares By Investing.com - Investing.com Australia
500: Something went wrong - Investing.com
180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks - Barchart
BMO maintains steady target on Korro Bio shares - Investing.com India
What is KRRO’s price-to-sales ratio telling us about the company’s value? - US Post News
Korro Bio (NASDAQ:KRRO) Shares Gap UpTime to Buy? - MarketBeat
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet - Yahoo Finance UK
RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg
Millennium Management LLC Purchases 23,307 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 11.9% in September - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
Point72 Asset Management L.P. Raises Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
NEA Management Company LLC Boosts Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Bought by Bank of New York Mellon Corp - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Bank of New York Mellon Corp - Defense World
Tri Locum Partners LP Takes Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Brown Brothers Harriman & Co. Acquires Shares of 813 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Stock Surge: Corcept Therapeutics Inc (CORT) Closes at 40.92, Marking a -3.19 Increase/Decrease - The Dwinnex
Korro Bio, Inc. Forecasted to Post Q3 2024 Earnings of ($2.79) Per Share (NASDAQ:KRRO) - MarketBeat
Korro Bio (NASDAQ:KRRO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Korro Bio (NASDAQ:KRRO) Given “Outperform” Rating at Royal Bank of Canada - Defense World
Novo Nordisk and Korro Bio Take RNA Editing to Cardiometabolic Diseases - Inside Precision Medicine
Korvest Ltd Director Buys First Shares - TipRanks
Korro Bio - The Pharma Letter
ORGN stock touches 52-week high at $1.73 amid market optimism - Investing.com Australia
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):